IL95031A
(en)
|
1989-07-18 |
2007-03-08 |
Amgen Inc |
A method of producing a recombinant human necrotic factor absorber
|
US6552170B1
(en)
*
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
US7429646B1
(en)
|
1995-06-05 |
2008-09-30 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor-like 2
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US5908624A
(en)
*
|
1996-06-27 |
1999-06-01 |
Albany Medical College |
Antigenic modulation of cells
|
US6713061B1
(en)
|
1996-03-12 |
2004-03-30 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
WO1997033904A1
(en)
|
1996-03-12 |
1997-09-18 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
US7357927B2
(en)
|
1996-03-12 |
2008-04-15 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
US6635743B1
(en)
|
1996-03-22 |
2003-10-21 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule II and methods of use
|
US7964190B2
(en)
|
1996-03-22 |
2011-06-21 |
Human Genome Sciences, Inc. |
Methods and compositions for decreasing T-cell activity
|
US8007784B1
(en)
|
1996-06-27 |
2011-08-30 |
Albany Medical College |
Antigenic modulation of cells
|
TW555765B
(en)
|
1996-07-09 |
2003-10-01 |
Amgen Inc |
Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
|
US6455040B1
(en)
|
1997-01-14 |
2002-09-24 |
Human Genome Sciences, Inc. |
Tumor necrosis factor receptor 5
|
US6433147B1
(en)
|
1997-01-28 |
2002-08-13 |
Human Genome Sciences, Inc. |
Death domain containing receptor-4
|
US8329179B2
(en)
|
1997-01-28 |
2012-12-11 |
Human Genome Sciences, Inc. |
Death domain containing receptor 4 antibodies and methods
|
PT1012274E
(pt)
|
1997-01-28 |
2007-08-14 |
Craig A Rosen |
Receptor 4 contendo um domínio de morte (dm4; receptor de morte 4), membro da super-família do ftn e ligação a liart (ap02)
|
US7452538B2
(en)
|
1997-01-28 |
2008-11-18 |
Human Genome Sciences, Inc. |
Death domain containing receptor 4 antibodies and methods
|
JP2001508783A
(ja)
*
|
1997-01-29 |
2001-07-03 |
ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー |
Peg化法
|
US6872568B1
(en)
|
1997-03-17 |
2005-03-29 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5 antibodies
|
US5985263A
(en)
*
|
1997-12-19 |
1999-11-16 |
Enzon, Inc. |
Substantially pure histidine-linked protein polymer conjugates
|
WO1999045026A1
(en)
*
|
1998-03-05 |
1999-09-10 |
Chiron Corporation |
Method for increasing the serum half-life of a biologically active molecule
|
US6066673A
(en)
*
|
1998-03-12 |
2000-05-23 |
The Procter & Gamble Company |
Enzyme inhibitors
|
US6942859B2
(en)
|
1998-03-13 |
2005-09-13 |
University Of Southern California |
Red blood cells covalently bound with polymers
|
US6312685B1
(en)
|
1998-03-13 |
2001-11-06 |
Timothy C. Fisher |
Red blood cells covalently bound with two different polyethylene glycol derivatives
|
US6686446B2
(en)
|
1998-03-19 |
2004-02-03 |
The Regents Of The University Of California |
Methods and compositions for controlled polypeptide synthesis
|
US6632922B1
(en)
|
1998-03-19 |
2003-10-14 |
The Regents Of The University Of California |
Methods and compositions for controlled polypeptide synthesis
|
WO2000050620A2
(en)
|
1999-02-26 |
2000-08-31 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
DE60022170T2
(de)
*
|
1999-03-09 |
2006-02-23 |
Rhodia Chimie |
Sulfoniertes copolymer und verfahren zur reinigung von oberflächen und/oder zur herstellung von flecken abweisenden eigenschaften dieser oberflächen und/oder zur entfernung von flecken oder verschmutzungen
|
EP1189928A1
(en)
*
|
1999-05-10 |
2002-03-27 |
The Regents Of The University Of California |
Methods and compositions for controlled polypeptide synthesis
|
ATE435033T1
(de)
|
2000-01-10 |
2009-07-15 |
Maxygen Holdings Ltd |
G-csf konjugate
|
RU2278123C2
(ru)
|
2000-02-11 |
2006-06-20 |
Максиджен Холдингз Лтд. |
Молекулы, подобные фактору vii или viia
|
AU2001259063A1
(en)
|
2000-04-12 |
2001-10-30 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
AU2001282856A1
(en)
|
2000-06-15 |
2001-12-24 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
EP1339746A2
(en)
|
2000-08-18 |
2003-09-03 |
Dyax Corp. |
Binding polypeptides for b lymphocyte stimulator protein (blys)
|
EP1324779B1
(en)
*
|
2000-09-29 |
2011-07-20 |
Schering Corporation |
Pegylated interleukin-10
|
JP5170931B2
(ja)
|
2000-10-16 |
2013-03-27 |
中外製薬株式会社 |
Peg修飾エリスロポエチン
|
BR0207576A
(pt)
|
2001-02-27 |
2004-04-27 |
Maxygen Aps |
Variante glicosilada de um polipeptìdeo de interferon beta precursor (ifnb), processos de aumentar a glicosilação in vivo de uma molécula de ifnb precursora, de produzir uma molécula de ifnb glicosilada, para preparar uma variante conjugada e de tratar um mamìfero com esclerose múltiplam composição farmacêutica, molécula de ifnb variante, sequência de nucleotìdeo, vetor de expressão, célula hospedeira de glicosilação conjugado, e, uso de um conjugado
|
DK1572874T3
(da)
|
2001-05-25 |
2013-12-16 |
Human Genome Sciences Inc |
Antistoffer, der immunospecifikt binder til TRAIL receptorer
|
NZ532427A
(en)
|
2001-09-24 |
2008-07-31 |
Imp Innovations Ltd |
Modification of feeding behavior using PYY (peptide YY) and its agonists such as NPY (neuropeptide Y)
|
EP1463751B1
(en)
|
2001-12-21 |
2013-05-22 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
CA2472882A1
(en)
|
2002-01-10 |
2003-07-17 |
Imperial College Innovations Ltd |
Use of pyy and glp-1, or an agonist thereof, for the modification of feeding behaviour
|
DE10209821A1
(de)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung von Proteinen an ein modifiziertes Polysaccharid
|
UA86744C2
(en)
|
2002-06-21 |
2009-05-25 |
Ново Нордиск Хэлс Кеа Аг |
Pegylated factor vii glycoforms
|
US7432331B2
(en)
|
2002-12-31 |
2008-10-07 |
Nektar Therapeutics Al, Corporation |
Hydrolytically stable maleimide-terminated polymers
|
WO2004060965A2
(en)
|
2002-12-31 |
2004-07-22 |
Nektar Therapeutics Al, Corporation |
Hydrolytically stable maleimide-terminated polymers
|
EP2261244A3
(en)
|
2003-04-15 |
2011-02-23 |
Glaxosmithkline LLC |
Human il-18 substitution mutants and their conjugates
|
US20040249119A1
(en)
*
|
2003-06-05 |
2004-12-09 |
Fox Martin Edward |
Novel mPEG propionaldehyde precursor
|
WO2005014655A2
(en)
|
2003-08-08 |
2005-02-17 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyalkyl starch and a protein
|
US20080206182A1
(en)
*
|
2003-08-08 |
2008-08-28 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of a Polymer and a Protein Linked by an Oxime Group
|
DE602004029173D1
(de)
|
2003-10-10 |
2010-10-28 |
Novo Nordisk As |
Il-21-derivate
|
EP2641611A3
(en)
|
2003-10-17 |
2013-12-18 |
Novo Nordisk A/S |
Combination therapy
|
JP2007519422A
(ja)
|
2004-02-02 |
2007-07-19 |
アンブレツクス・インコーポレイテツド |
修飾されたヒト四螺旋バンドルポリペプチド及びそれらの使用
|
EP1729795B1
(en)
|
2004-02-09 |
2016-02-03 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US7973139B2
(en)
|
2004-03-26 |
2011-07-05 |
Human Genome Sciences, Inc. |
Antibodies against nogo receptor
|
MXPA06014684A
(es)
|
2004-06-18 |
2007-02-12 |
Ambrx Inc |
Novedosos polipeptidos de enlace antigeno y sus usos.
|
EP1768700B1
(en)
*
|
2004-07-16 |
2010-12-15 |
Nektar Therapeutics |
Conjugates comprising gm-csf and a polymer
|
BRPI0519430A2
(pt)
|
2004-12-22 |
2009-02-10 |
Ambrx Inc |
hormânio do crescimento humano modificado
|
ATE541934T1
(de)
|
2004-12-22 |
2012-02-15 |
Ambrx Inc |
Zusammensetzungen von aminoacyl-trna-synthetase und verwendungen davon
|
AU2005322019B2
(en)
|
2004-12-22 |
2010-08-26 |
Ambrx, Inc. |
Formulations of human growth hormone comprising a non-naturally encoded amino acid
|
SG161210A1
(en)
|
2004-12-22 |
2010-05-27 |
Ambrx Inc |
Methods for expression and purification of recombinant human growth hormone
|
WO2006089228A2
(en)
|
2005-02-16 |
2006-08-24 |
Nektar Therapeutics Al, Corporation |
Conjugates of an epo moiety and a polymer
|
KR20080026135A
(ko)
|
2005-06-03 |
2008-03-24 |
암브룩스, 인코포레이티드 |
개선된 인간 인터페론 분자 및 이의 용도
|
EP2360170A3
(en)
|
2005-06-17 |
2012-03-28 |
Novo Nordisk Health Care AG |
Selective reduction and derivatization of engineered proteins comprinsing at least one non-native cysteine
|
JP4879988B2
(ja)
|
2005-09-29 |
2012-02-22 |
メルク・シャープ・エンド・ドーム・コーポレイション |
メラノコルチン−4受容体モジュレーターとしてのアシル化スピロピペリジン誘導体
|
CA2626082C
(en)
|
2005-10-13 |
2017-04-11 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive disease
|
WO2007047997A2
(en)
|
2005-10-19 |
2007-04-26 |
Smartcells, Inc. |
Methods for reducing the mitogenicity of lectin compositions
|
EP2339014B1
(en)
|
2005-11-16 |
2015-05-27 |
Ambrx, Inc. |
Methods and compositions comprising non-natural amino acids
|
WO2007087673A1
(en)
|
2006-02-01 |
2007-08-09 |
Arana Therapeutics Limited |
Domain antibody construct
|
EP2573111A1
(en)
|
2006-04-20 |
2013-03-27 |
Amgen Inc. |
GLP-1 compounds
|
US20090252720A1
(en)
|
2006-05-24 |
2009-10-08 |
Novo Nordisk Health Care Ag |
Prolonged FIX Analogues and Derivatives
|
US8420792B2
(en)
|
2006-09-08 |
2013-04-16 |
Ambrx, Inc. |
Suppressor tRNA transcription in vertebrate cells
|
NZ574721A
(en)
|
2006-09-08 |
2012-02-24 |
Ambrx Inc |
Hybrid suppressor trna for vertebrate cells
|
EP2069396B1
(en)
|
2006-09-08 |
2015-10-21 |
Ambrx, Inc. |
Modified human plasma polypeptide or fc scaffolds and their uses
|
EP2083831B1
(en)
|
2006-09-22 |
2013-12-25 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
BRPI0809583B1
(pt)
|
2007-03-30 |
2022-02-22 |
Ambrx, Inc |
Polipeptídeo fgf-21 modificado, composição compreendendo o mesmo, método para produzir o referido polipetídeo fgf-21 e célula compreendendo um polinucleotídeo
|
EP2145884B1
(en)
|
2007-04-02 |
2014-08-06 |
Msd K.K. |
Indoledione derivative
|
CA2685596A1
(en)
|
2007-05-02 |
2008-11-13 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
NZ603812A
(en)
|
2007-11-20 |
2014-06-27 |
Ambrx Inc |
Modified insulin polypeptides and their uses
|
US9181327B2
(en)
|
2008-01-07 |
2015-11-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-HIV domain antibodies and method of making and using same
|
SG188143A1
(en)
|
2008-02-08 |
2013-03-28 |
Ambrx Inc |
Modified leptin polypeptides and their uses
|
EP2260102A1
(en)
|
2008-03-25 |
2010-12-15 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by down-regulating frizzled-4 and/or frizzled-1
|
NZ591235A
(en)
|
2008-07-23 |
2012-07-27 |
Ambrx Inc |
Modified bovine g-csf polypeptides comprising non natural amino acid and their uses treating infections such as mastitis
|
PL2342223T3
(pl)
|
2008-09-26 |
2017-09-29 |
Ambrx, Inc. |
Zmodyfikowane polipeptydy zwierzęcej erytropoetyny i ich zastosowania
|
TR201802361T4
(tr)
|
2008-09-26 |
2018-03-21 |
Ambrx Inc |
Doğal olmayan amino asit replikasyonuna bağımlı mikroorganizmalar ve aşılar.
|
US8691205B2
(en)
|
2008-12-17 |
2014-04-08 |
Merck Sharp & Dohme Corporation |
Mono- and di-PEG IL-10 production; and uses
|
EP2391217A4
(en)
|
2009-01-28 |
2015-05-20 |
Smartcells Inc |
SYNTHETIC CONJUGATES AND USES THEREOF
|
WO2010100247A1
(en)
|
2009-03-06 |
2010-09-10 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Novel therapy for anxiety
|
WO2010107519A1
(en)
|
2009-03-20 |
2010-09-23 |
Smartcells, Inc. |
Terminally-functionalized conjugates and uses thereof
|
US8580732B2
(en)
|
2009-04-07 |
2013-11-12 |
Duke University |
Peptide therapy for hyperglycemia
|
EP2241323A1
(en)
|
2009-04-14 |
2010-10-20 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tenascin-W and brain cancers
|
EP2292266A1
(en)
|
2009-08-27 |
2011-03-09 |
Novartis Forschungsstiftung, Zweigniederlassung |
Treating cancer by modulating copine III
|
EP2480573A1
(en)
|
2009-09-22 |
2012-08-01 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mex-3
|
WO2011045352A2
(en)
|
2009-10-15 |
2011-04-21 |
Novartis Forschungsstiftung |
Spleen tyrosine kinase and brain cancers
|
MX366890B
(es)
|
2009-10-23 |
2019-07-30 |
Millennium Pharm Inc |
Moléculas de anticuerpo anti - gcc y composiciones y métodos relacionados.
|
US20120213801A1
(en)
|
2009-10-30 |
2012-08-23 |
Ekaterina Gresko |
Phosphorylated Twist1 and cancer
|
CN104017063A
(zh)
|
2009-12-21 |
2014-09-03 |
Ambrx公司 |
经过修饰的猪促生长素多肽和其用途
|
NZ600361A
(en)
|
2009-12-21 |
2014-06-27 |
Ambrx Inc |
Modified bovine somatotropin polypeptides and their uses
|
JP6148013B2
(ja)
|
2010-03-05 |
2017-06-14 |
リグショスピタレト |
補体活性化のキメラ抑制分子
|
WO2011107586A1
(en)
|
2010-03-05 |
2011-09-09 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, |
Smoc1, tenascin-c and brain cancers
|
EP2561076A1
(en)
|
2010-04-19 |
2013-02-27 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Modulating xrn1
|
EP2569331A1
(en)
|
2010-05-10 |
2013-03-20 |
Perseid Therapeutics LLC |
Polypeptide inhibitors of vla4
|
US20130089538A1
(en)
|
2010-06-10 |
2013-04-11 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh |
Treating cancer by modulating mammalian sterile 20-like kinase 3
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
MY162837A
(en)
|
2010-08-17 |
2017-07-31 |
Ambrx Inc |
Modified relaxin polypeptides and their uses
|
EP2614080A1
(en)
|
2010-09-10 |
2013-07-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Phosphorylated twist1 and metastasis
|
AR083006A1
(es)
|
2010-09-23 |
2013-01-23 |
Lilly Co Eli |
Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
|
EP2640738A1
(en)
|
2010-11-15 |
2013-09-25 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Anti-fungal agents
|
EP2474612A1
(en)
|
2011-01-05 |
2012-07-11 |
University College Dublin, National University of Ireland Dublin |
Affinity separation means, and uses thereof to separate, purify or concentrate a target molecule
|
EP2717911A1
(en)
|
2011-06-06 |
2014-04-16 |
Novartis Forschungsstiftung, Zweigniederlassung |
Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
|
CN103930440A
(zh)
|
2011-07-01 |
2014-07-16 |
拜耳知识产权有限责任公司 |
松弛素融合多肽及其用途
|
WO2013068432A1
(en)
|
2011-11-08 |
2013-05-16 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Early diagnostic of neurodegenerative diseases
|
US20140314787A1
(en)
|
2011-11-08 |
2014-10-23 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute |
Treatment for neurodegenerative diseases
|
WO2013102825A1
(en)
|
2012-01-02 |
2013-07-11 |
Novartis Ag |
Cdcp1 and breast cancer
|
US8993614B2
(en)
|
2012-03-15 |
2015-03-31 |
F. Hoffmann-La Roche Ag |
Substituted pyrrolidine-2-carboxamides
|
EP2831112A1
(en)
|
2012-03-29 |
2015-02-04 |
Friedrich Miescher Institute for Biomedical Research |
Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
|
US9156915B2
(en)
|
2012-04-26 |
2015-10-13 |
Thomas Jefferson University |
Anti-GCC antibody molecules
|
EP2859017B1
(en)
|
2012-06-08 |
2019-02-20 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
DK2863955T3
(en)
|
2012-06-26 |
2017-01-23 |
Sutro Biopharma Inc |
MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
|
EP2866831A1
(en)
|
2012-06-29 |
2015-05-06 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating diseases by modulating a specific isoform of mkl1
|
US20150184154A1
(en)
|
2012-07-05 |
2015-07-02 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear |
New treatment for neurodegenerative diseases
|
EP3584255B1
(en)
|
2012-08-31 |
2022-02-16 |
Sutro Biopharma, Inc. |
Modified amino acids comprising an azido group
|
US9943568B2
(en)
|
2013-04-18 |
2018-04-17 |
Armo Biosciences, Inc. |
Methods of using pegylated interleukin-10 for treating cancer
|
ES2688206T3
(es)
|
2013-06-17 |
2018-10-31 |
Armo Biosciences, Inc. |
Procedimiento de evaluación de la identidad y la estabilidad de proteínas
|
US9764039B2
(en)
|
2013-07-10 |
2017-09-19 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
EP3030902B1
(en)
|
2013-08-07 |
2019-09-25 |
Friedrich Miescher Institute for Biomedical Research |
New screening method for the treatment friedreich's ataxia
|
CN105658232A
(zh)
|
2013-08-30 |
2016-06-08 |
阿尔莫生物科技股份有限公司 |
使用白细胞介素-10治疗疾病和病症的方法
|
US9840493B2
(en)
|
2013-10-11 |
2017-12-12 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
WO2015070060A1
(en)
|
2013-11-11 |
2015-05-14 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
EP3134439B1
(en)
|
2014-04-21 |
2018-12-26 |
Millennium Pharmaceuticals, Inc. |
Anti-psyk antibody molecules and use of same for syk-targeted therapy
|
US10293043B2
(en)
|
2014-06-02 |
2019-05-21 |
Armo Biosciences, Inc. |
Methods of lowering serum cholesterol
|
WO2015189816A1
(en)
|
2014-06-13 |
2015-12-17 |
Friedrich Miescher Institute For Biomedical Research |
New treatment against influenza virus
|
US10308935B2
(en)
|
2014-06-23 |
2019-06-04 |
Friedrich Miescher Institute For Biomedical Research |
Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small RNAS
|
US20170298360A1
(en)
|
2014-09-24 |
2017-10-19 |
Friedrich Miescher Institute For Biomedical Research |
Lats and breast cancer
|
MX2017004838A
(es)
|
2014-10-14 |
2017-10-16 |
Armo Biosciences Inc |
Composiciones de interleucina-15 y usos de estas.
|
AU2015336101A1
(en)
|
2014-10-22 |
2017-04-20 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
UY36370A
(es)
|
2014-10-24 |
2016-04-29 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Polipéptidos fgf-21 modificados y sus usos
|
US10618970B2
(en)
|
2015-02-03 |
2020-04-14 |
Armo Biosciences, Inc. |
Method of treating cancer with IL-10 and antibodies that induce ADCC
|
EP3302547A1
(en)
|
2015-05-28 |
2018-04-11 |
Armo Biosciences, Inc. |
Pegylated interleukin-10 for use in treating cancer
|
WO2017027545A1
(en)
|
2015-08-12 |
2017-02-16 |
Cell Machines, Inc. |
Methods and compositions related to long half-life coagulation complexes
|
EP3341012A4
(en)
|
2015-08-25 |
2019-03-20 |
Armo Biosciences, Inc. |
METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
|
US20180348224A1
(en)
|
2015-10-28 |
2018-12-06 |
Friedrich Miescher Institute For Biomedical Resear Ch |
Tenascin-w and biliary tract cancers
|
ES2963839T3
(es)
|
2017-02-08 |
2024-04-02 |
Bristol Myers Squibb Co |
Polipéptidos de relaxina modificados que comprenden un potenciador farmacocinético y usos de los mismos
|
EP3664828A1
(en)
|
2017-08-10 |
2020-06-17 |
Friedrich Miescher Institute for Biomedical Research |
Hdac6 and protein aggregation
|
HRP20240016T1
(hr)
|
2018-09-11 |
2024-03-29 |
Ambrx, Inc. |
Konjugati polipeptida interleukina-2 i njihove uporabe
|
CN113366015A
(zh)
|
2018-10-19 |
2021-09-07 |
Ambrx公司 |
白细胞介素-10多肽缀合物、其二聚体及其用途
|
BR112021015832A2
(pt)
|
2019-02-12 |
2022-01-18 |
Ambrx Inc |
Composições que contêm conjugados de anticorpo-agonista de tlr, métodos e usos dos mesmos
|
WO2021183832A1
(en)
|
2020-03-11 |
2021-09-16 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and methods of use thereof
|
AU2021327396A1
(en)
|
2020-08-20 |
2023-03-23 |
Ambrx, Inc. |
Antibody-TLR agonist conjugates, methods and uses thereof
|
TW202237638A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
|
TW202237639A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
鳥苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
|
AU2022219373A1
(en)
|
2021-02-15 |
2023-08-24 |
Takeda Pharmaceutical Company Limited |
Cell therapy compositions and methods for modulating tgf-b signaling
|
AU2022249223A1
(en)
|
2021-04-03 |
2023-10-12 |
Ambrx, Inc. |
Anti-her2 antibody-drug conjugates and uses thereof
|